Differences
This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revision | Both sides next revision | ||
coronavirus [2023/01/25 20:08] pamela [Lab Leaks] | coronavirus [2023/01/25 20:16] (current) pamela [Study - MERS-CoV spike nanoparticles] | ||
---|---|---|---|
Line 49: | Line 49: | ||
Copyright © 2017 Elsevier Ltd. All rights reserved.((https:// | Copyright © 2017 Elsevier Ltd. All rights reserved.((https:// | ||
+ | ==== HIV SARS Spike Protein ==== | ||
+ | |||
+ | Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors | ||
+ | J Gen Virol. 2018 May; | ||
+ | Authors - Jeanne M Sisk 1 , Matthew B Frieman | ||
+ | |||
+ | Abstract | ||
+ | |||
+ | Enveloped viruses gain entry into host cells by fusing with cellular membranes, a step that is required for virus replication. Coronaviruses, | ||
+ | |||
+ | The virus spike (S) protein mediates fusion with the host cell membrane. We have shown previously that an Abelson (Abl) kinase inhibitor, imatinib, significantly reduces SARS-CoV and MERS-CoV viral titres and prevents endosomal entry by [[:HIV SARS S]] and MERS S pseudotyped virions. SARS-CoV and MERS-CoV are classified as BSL-3 viruses, which makes experimentation into the cellular mechanisms involved in infection more challenging. | ||
+ | |||
+ | Here, we use IBV, a BSL-2 virus, as a model for studying the role of Abl kinase activity during coronavirus infection. We found that imatinib and two specific Abl kinase inhibitors, GNF2 and GNF5, reduce IBV titres by blocking the first round of virus infection. Additionally, | ||
+ | |||
+ | Keywords: Abl kinase; Abl1; Abl2; GNF2; GNF5; IBV; MERS-CoV; SARS-CoV; cell-cell fusion; coronavirus; | ||
+ | Publication types - Research Support, N.I.H., Extramural((https:// | ||